Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases

Premila Wencesiaus Ashok, Alexander Allan Templeton, Prabhath Thanuja Wagaarachchi, G. M. Flett

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

We assessed the effectiveness, safety and factors that affected the outcome of midtrimester medical termination of pregnancy at 13-21 weeks gestation. Of the 1002 women, 3 took mifepristone and decided to continue with the pregnancy, with 999 women being compliant with the regimen. Of these, 2 women aborted prior to administration of misoprostol and 970 (97.1%) aborted successfully within five doses of misoprostol. Surgical intervention was necessary to complete the abortion process in 81 (8.1%) women. Women with no previous pregnancy (p = 0.02), no previous live birth (p = 0.0001) and gestations 17-21 weeks (p = 0.001) required more prostaglandin. Younger women (p = 0.0001) and women with a previous live birth (p = 0.001) were more likely to have a successful abortion. The induction abortion interval was significantly longer with increasing gestation [95% confidence interval (CI) difference in means: -2.52 to -0.89, p = 0.0001], increasing age (p = 0.0001) and no previous live birth (95% Cl difference in means: -0.25 to -1.01, p = 0.0001). Surgical intervention was more likely to be required with increasing age (p = 0.008). Mifepristone in combination with misoprostol is a safe and effective regimen for midtrimester medical abortion with younger women and those with a previous live birth more likely to have a successful abortion. (C) 2004 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)51-58
Number of pages7
JournalContraception
Volume69
Issue number1
DOIs
Publication statusPublished - 2004

Keywords

  • mifepristone
  • misoprostol
  • midtrimester medical abortion
  • 2ND TRIMESTER ABORTION
  • MIFEPRISTONE RU-486
  • 2ND-TRIMESTER PREGNANCY
  • VAGINAL MISOPROSTOL
  • GEMEPROST
  • INDUCTION
  • REGIMENS

Cite this

Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. / Ashok, Premila Wencesiaus; Templeton, Alexander Allan; Wagaarachchi, Prabhath Thanuja; Flett, G. M.

In: Contraception, Vol. 69, No. 1, 2004, p. 51-58.

Research output: Contribution to journalArticle

@article{feba2ba719b84d8e8b49a7b3b4725e31,
title = "Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases",
abstract = "We assessed the effectiveness, safety and factors that affected the outcome of midtrimester medical termination of pregnancy at 13-21 weeks gestation. Of the 1002 women, 3 took mifepristone and decided to continue with the pregnancy, with 999 women being compliant with the regimen. Of these, 2 women aborted prior to administration of misoprostol and 970 (97.1{\%}) aborted successfully within five doses of misoprostol. Surgical intervention was necessary to complete the abortion process in 81 (8.1{\%}) women. Women with no previous pregnancy (p = 0.02), no previous live birth (p = 0.0001) and gestations 17-21 weeks (p = 0.001) required more prostaglandin. Younger women (p = 0.0001) and women with a previous live birth (p = 0.001) were more likely to have a successful abortion. The induction abortion interval was significantly longer with increasing gestation [95{\%} confidence interval (CI) difference in means: -2.52 to -0.89, p = 0.0001], increasing age (p = 0.0001) and no previous live birth (95{\%} Cl difference in means: -0.25 to -1.01, p = 0.0001). Surgical intervention was more likely to be required with increasing age (p = 0.008). Mifepristone in combination with misoprostol is a safe and effective regimen for midtrimester medical abortion with younger women and those with a previous live birth more likely to have a successful abortion. (C) 2004 Elsevier Inc. All rights reserved.",
keywords = "mifepristone, misoprostol, midtrimester medical abortion, 2ND TRIMESTER ABORTION, MIFEPRISTONE RU-486, 2ND-TRIMESTER PREGNANCY, VAGINAL MISOPROSTOL, GEMEPROST, INDUCTION, REGIMENS",
author = "Ashok, {Premila Wencesiaus} and Templeton, {Alexander Allan} and Wagaarachchi, {Prabhath Thanuja} and Flett, {G. M.}",
year = "2004",
doi = "10.1016/j.contraception.2003.09.006",
language = "English",
volume = "69",
pages = "51--58",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases

AU - Ashok, Premila Wencesiaus

AU - Templeton, Alexander Allan

AU - Wagaarachchi, Prabhath Thanuja

AU - Flett, G. M.

PY - 2004

Y1 - 2004

N2 - We assessed the effectiveness, safety and factors that affected the outcome of midtrimester medical termination of pregnancy at 13-21 weeks gestation. Of the 1002 women, 3 took mifepristone and decided to continue with the pregnancy, with 999 women being compliant with the regimen. Of these, 2 women aborted prior to administration of misoprostol and 970 (97.1%) aborted successfully within five doses of misoprostol. Surgical intervention was necessary to complete the abortion process in 81 (8.1%) women. Women with no previous pregnancy (p = 0.02), no previous live birth (p = 0.0001) and gestations 17-21 weeks (p = 0.001) required more prostaglandin. Younger women (p = 0.0001) and women with a previous live birth (p = 0.001) were more likely to have a successful abortion. The induction abortion interval was significantly longer with increasing gestation [95% confidence interval (CI) difference in means: -2.52 to -0.89, p = 0.0001], increasing age (p = 0.0001) and no previous live birth (95% Cl difference in means: -0.25 to -1.01, p = 0.0001). Surgical intervention was more likely to be required with increasing age (p = 0.008). Mifepristone in combination with misoprostol is a safe and effective regimen for midtrimester medical abortion with younger women and those with a previous live birth more likely to have a successful abortion. (C) 2004 Elsevier Inc. All rights reserved.

AB - We assessed the effectiveness, safety and factors that affected the outcome of midtrimester medical termination of pregnancy at 13-21 weeks gestation. Of the 1002 women, 3 took mifepristone and decided to continue with the pregnancy, with 999 women being compliant with the regimen. Of these, 2 women aborted prior to administration of misoprostol and 970 (97.1%) aborted successfully within five doses of misoprostol. Surgical intervention was necessary to complete the abortion process in 81 (8.1%) women. Women with no previous pregnancy (p = 0.02), no previous live birth (p = 0.0001) and gestations 17-21 weeks (p = 0.001) required more prostaglandin. Younger women (p = 0.0001) and women with a previous live birth (p = 0.001) were more likely to have a successful abortion. The induction abortion interval was significantly longer with increasing gestation [95% confidence interval (CI) difference in means: -2.52 to -0.89, p = 0.0001], increasing age (p = 0.0001) and no previous live birth (95% Cl difference in means: -0.25 to -1.01, p = 0.0001). Surgical intervention was more likely to be required with increasing age (p = 0.008). Mifepristone in combination with misoprostol is a safe and effective regimen for midtrimester medical abortion with younger women and those with a previous live birth more likely to have a successful abortion. (C) 2004 Elsevier Inc. All rights reserved.

KW - mifepristone

KW - misoprostol

KW - midtrimester medical abortion

KW - 2ND TRIMESTER ABORTION

KW - MIFEPRISTONE RU-486

KW - 2ND-TRIMESTER PREGNANCY

KW - VAGINAL MISOPROSTOL

KW - GEMEPROST

KW - INDUCTION

KW - REGIMENS

U2 - 10.1016/j.contraception.2003.09.006

DO - 10.1016/j.contraception.2003.09.006

M3 - Article

VL - 69

SP - 51

EP - 58

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 1

ER -